第二届 BMT CTN 骨髓瘤协作组微小残留病和免疫特征分析年度研讨会纪要。
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
机构信息
Department of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, Nebraska.
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan.
出版信息
Biol Blood Marrow Transplant. 2019 Mar;25(3):e89-e97. doi: 10.1016/j.bbmt.2018.11.001. Epub 2018 Nov 5.
Abstract
The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.
摘要
第二届血液和骨髓移植临床研究网络（BMT CTN）多发性骨髓瘤协作组微小残留病和免疫分析研讨会于 2017 年 12 月 7 日在美国血液学会（ASH）会议上召开。在本次研讨会上，来自世界各地的研究人员展示了他们在多发性骨髓瘤微小残留病（MRD）评估和免疫分析（IP）方面的最新研究成果。本文总结了研讨会的演讲内容以及相关 ASH 摘要，并重点关注了在临床试验设计和实践中整合 MRD 和 IP 评估所涉及的监管问题。
相似文献
1
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant. 2019 Mar;25(3):e89-e97. doi: 10.1016/j.bbmt.2018.11.001. Epub 2018 Nov 5.
2
Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant. 2020 Jan;26(1):e7-e15. doi: 10.1016/j.bbmt.2019.09.015. Epub 2019 Sep 14.
3
BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.
Biol Blood Marrow Transplant. 2018 Apr;24(4):641-648. doi: 10.1016/j.bbmt.2017.12.774. Epub 2017 Dec 11.
4
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant. 2020 Oct;26(10):e247-e255. doi: 10.1016/j.bbmt.2020.06.011. Epub 2020 Jun 24.
5
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
Transplant Cell Ther. 2021 Oct;27(10):807-816. doi: 10.1016/j.jtct.2021.05.027. Epub 2021 Jun 6.
6
Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.
Transplant Cell Ther. 2022 Aug;28(8):446-454. doi: 10.1016/j.jtct.2022.05.019. Epub 2022 May 21.
7
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-2051. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30.
8
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
BMC Cancer. 2022 Feb 5;22(1):147. doi: 10.1186/s12885-022-09184-1.
9
Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.
Biol Blood Marrow Transplant. 2019 Mar;25(3):459-465. doi: 10.1016/j.bbmt.2018.11.015. Epub 2018 Nov 24.
10
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
Leukemia. 2021 Jan;35(1):18-30. doi: 10.1038/s41375-020-01012-4. Epub 2020 Aug 11.
引用本文的文献
1
Immunophenotypic Characteristics of Bone Marrow Microenvironment Cellular Composition at the Biochemical Progression of Multiple Myeloma.
J Clin Med. 2022 Jun 27;11(13):3722. doi: 10.3390/jcm11133722.
2
Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.
Transplant Cell Ther. 2022 Aug;28(8):446-454. doi: 10.1016/j.jtct.2022.05.019. Epub 2022 May 21.
3
Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.
Front Immunol. 2021 Jul 5;12:663748. doi: 10.3389/fimmu.2021.663748. eCollection 2021.
4
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
Transplant Cell Ther. 2021 Oct;27(10):807-816. doi: 10.1016/j.jtct.2021.05.027. Epub 2021 Jun 6.
5
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant. 2020 Oct;26(10):e247-e255. doi: 10.1016/j.bbmt.2020.06.011. Epub 2020 Jun 24.
6
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.
Biol Blood Marrow Transplant. 2020 Aug;26(8):1414-1424. doi: 10.1016/j.bbmt.2020.03.028. Epub 2020 Apr 20.
7
Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant. 2020 Jan;26(1):e7-e15. doi: 10.1016/j.bbmt.2019.09.015. Epub 2019 Sep 14.
8
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.
Front Oncol. 2019 Aug 20;9:699. doi: 10.3389/fonc.2019.00699. eCollection 2019.
9
Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
Curr Hematol Malig Rep. 2019 Feb;14(1):39-46. doi: 10.1007/s11899-019-0497-7.
本文引用的文献
1
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
J Clin Oncol. 2022 Sep 1;40(25):2889-2900. doi: 10.1200/JCO.21.02228. Epub 2022 Apr 4.
2
Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT.
Blood Adv. 2017 Jun 20;1(15):1056-1066. doi: 10.1182/bloodadvances.2017005447. eCollection 2017 Jun 27.
3
MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods.
Blood Adv. 2017 May 3;1(12):728-732. doi: 10.1182/bloodadvances.2016003715. eCollection 2017 May 9.
4
BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.
Biol Blood Marrow Transplant. 2018 Apr;24(4):641-648. doi: 10.1016/j.bbmt.2017.12.774. Epub 2017 Dec 11.
5
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.
Nat Commun. 2017 Aug 16;8(1):268. doi: 10.1038/s41467-017-00296-y.
6
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
J Clin Oncol. 2017 Oct 10;35(29):3279-3289. doi: 10.1200/JCO.2017.72.6679. Epub 2017 Jul 25.
7
Prospective Evaluation of Magnetic Resonance Imaging and [F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.
J Clin Oncol. 2017 Sep 1;35(25):2911-2918. doi: 10.1200/JCO.2017.72.2975. Epub 2017 Jul 7.
8
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
Leukemia. 2017 Oct;31(10):2094-2103. doi: 10.1038/leu.2017.29. Epub 2017 Jan 20.
9
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.
Blood Cancer J. 2016 Dec 16;6(12):e511. doi: 10.1038/bcj.2016.118.
10
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.
J Immunother Cancer. 2016 Nov 15;4:77. doi: 10.1186/s40425-016-0179-0. eCollection 2016.
Zotero 插件